Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zoster vaccine live (Changchun BCHT Biotechnology Co.)
- Development stage
- Approved
- Lead developer
- Changchun BCHT Biotechnology
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
BCHT's Herpes Zoster Vaccine (Live) is a live attenuated vaccine developed by Changchun BCHT Biotechnology Co. for the prevention of shingles (herpes zoster) in adults aged 40 years and older. It utilizes the Oka strain of the Varicella-Zoster Virus (VZV). In early 2023, it became the first domestically developed shingles vaccine to receive marketing approval from China's National Medical Products Administration (NMPA). Unlike the recombinant zoster vaccine (Shingrix), which requires two doses, this live attenuated vaccine is administered as a single dose. It works by boosting VZV-specific cell-mediated immunity, thereby preventing the reactivation of the latent virus in the sensory ganglia.
- Brand names
- Ganwei
- Other names
- BCHT shingles vaccineLive attenuated herpes zoster vaccine (BCHT)Herpes Zoster Vaccine, Live-Changchun BCHT Biotechnology Co.
Beyond the preview
Go deeper on zoster vaccine live (Changchun BCHT Biotechnology Co.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zoster vaccine live (Changchun BCHT Biotechnology Co.).